Reta 40

Reta 40 — Retatrutide 40mg Research Peptide Reta 40 contains 40mg of Retatrutide (LY3437943), a novel triple-acting receptor agonist that simultaneously targets glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This higher-concentration formulation is designed for advanced research protocols requiring larger doses per vial. Retatrutide represents a significant advancement in multi-receptor agonist research. Phase 2 clinical trial data demonstrated notable effects on body weight reduction and metabolic parameters, positioning it as a compound of considerable interest in metabolic research. Key Research Areas: - Triple receptor agonism (GIP/GLP-1/glucagon) - Metabolic pathway modulation studies - Energy homeostasis research - Appetite regulation pathway investigations - Glucose metabolism studies - Body composition research models Composition per vial: Retatrutide (LY3437943) — 40mg Storage: Store at -20°C for long-term stability. Reconstituted solutions should be stored at 2-8°C. Handling: Follow appropriate laboratory handling procedures. Disclaimer: This product is intended for research purposes only. Not for human consumption.